2KZ0 Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kezar Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.95 |
| 52 Week High | US$9.35 |
| 52 Week Low | US$4.18 |
| Beta | 0.19 |
| 1 Month Change | 0% |
| 3 Month Change | -2.11% |
| 1 Year Change | -15.24% |
| 3 Year Change | -94.81% |
| 5 Year Change | -80.37% |
| Change since IPO | -95.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2KZ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.3% |
| 1Y | -15.2% | -14.0% | 6.9% |
Return vs Industry: 2KZ0 underperformed the German Biotechs industry which returned -14% over the past year.
Return vs Market: 2KZ0 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 2KZ0 volatility | |
|---|---|
| 2KZ0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2KZ0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2KZ0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 58 | Chris Kirk | www.kezarlifesciences.com |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. Fundamentals Summary
| 2KZ0 fundamental statistics | |
|---|---|
| Market cap | €47.36m |
| Earnings (TTM) | -€92.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 2KZ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2KZ0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$72.35m |
| Gross Profit | -US$72.35m |
| Other Expenses | US$23.42m |
| Earnings | -US$95.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.7% |
How did 2KZ0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 16:45 |
| End of Day Share Price | 2024/10/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kezar Life Sciences, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Maurice Raycroft | Jefferies LLC |
| Catherine Novack | JonesTrading Institutional Services, LLC |